A multicenter Phase 3 trial in India found that generic semaglutide delivered non-inferior blood sugar reduction and comparable weight loss versus the innovator product in adults with type 2 diabetes. The study adds to the evidence base supporting generic incretin manufacturing and reimbursement pathways in emerging markets. The report describes efficacy outcomes aligned on glycemic endpoints and body-weight changes, with the same overall comparative intent typically required for biosimilar-like substitution decisions—even though semaglutide’s regulatory status can vary by jurisdiction. For clinicians and commercial teams, the result supports expansion of access strategies while preserving clinical performance benchmarks that matter to payors and prescribing physicians.